Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, Austria, Australia, Canada, Denmark, France, Germany, Italy, New Zealand, Poland, Read more…
Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news can be disappointing, the HD Community will keep positive and Read more…
IHA interviews Robert Pacifici from CHDI IHA interviews Robert Pacifici from CHDI IHA interviews Robert Pacifici from CHDI IHA interviews Robert Pacifici from CHDI Svein Olaf Olsen, President of the International Huntington Association, interviews Robert Pacifici, the Chief Scientific Officer Read more…
International Huntington Association has received a very generous donation. A Norwegian donor is behind the donation. He wishes to remain anonymous. The money is earmarked for a new position at IHA’s office in Lisbon and is given under this condition. Read more…
Have you heard of the Joyvest by Lyckna? It’s an activity vest that plays music when you move! Carina, from the Huntington’s Disease Association (RHS) in Sweden makes a demonstration. This is a physical therapy, highly recomended for working and Read more…
A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 (the name of the study drug) for Huntington’s Disease (HD.) Read more…
The 2022 Huntington’s Disease (HD) Latin American Conference brings together leading international representatives of the HD community – clinicians, scientists, social workers, students, family associations, affected individuals, and at-risk youth. Despite its international character, the conference is and will always Read more…
September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 or 60 mg; mean mHTT reduction across both cohorts was Read more…
Topics presented during the EHDN2022 Plenary Meeting will contain reports on recent advances in HD research (in both basic and clinical sciences). Aside from participating in the plenary and other parallel sessions, attendees will also have the opportunity to meet Read more…
This is a story of hope. Sherry Lazaruk and her son, Trevor Strutt, are both diagnosed with Huntington’s Disease. Sherry was diagnosed when she turned 30 and Trevor was diagnosed 5 years ago. Trevor decided to test himself not to Read more…
Arabic